The Sharabi lab is focused on understanding the fundamental interactions between radiation and the immune system and identifying strategies to combine radiation with immunotherapy. Dr. Sharabi published one of the first studies demonstrating that stereotactic radiation can synergize with anti-PD-1 checkpoint blockade immunotherapy. Additionally his work demonstrated that stereotactic radiation can induce antigen-specific memory T-cells. His long term goal is to directly advance patient care and improve outcomes in cancer patients though translational research.
While at Johns Hopkins, Dr. Sharabi published one of the first studies combining stereotactic radiation with anti-PD-1 checkpoint blockade immunotherapy. His work identified a role for stereotactic radiation in inducing antigen specific anti-tumor immune responses and that antigen cross presentation may be required for the immune stimulatory effects of radiation. Additionally his work demonstrated that stereotactic radiation can induce antigen-specific memory T-cells.
In order to translate these findings Dr. Sharabi is involved in a number of clinical trials. He is a Co-Investigator on J1382: A Pilot Study of Stereotactic RadioSurgery combined with Ipilimumab in Patients with Newly Diagnosed Melanoma Metastases in the Brain and Spine at Johns Hopkins Hospital. He is also a Co-Investigator on J13158: Evaluation of Immunologic Responses in HPV-Associated Oropharyngeal Carcinoma Patients Receiving Chemoradiation Therapy at Johns Hopkins Hospital. At UC San Diego he is the Principle Investigator on a Phase II Randomized study to determine the benefit of adding SBRT to checkpoint blockade immunotherapy. Research blood draws from these clinical trials will be taken back to the lab and analyzed to identify the next generation of research projects.